背景:登革病毒(DENV)是最广泛的虫媒病毒。世界卫生组织(WHO)宣布登革热为2019年全球十大健康威胁之一。然而,它在文献计量分析中代表性不足。本研究采用文献计量分析来确定研究热点和趋势,全面概述了该领域当前的研究动态。
结果:我们提供了一份1995年至2023年的报告,该报告提供了登革病毒(DENV)研究的独特纵向分析,揭示了以前文献中未广泛涵盖的重大趋势和变化。共审议了10,767份与DENV相关的文件,随着出版物的显著增加,2021年达到747篇文章的峰值。Plos被忽视的热带病已成为登革热病毒研究的主要杂志,在这一领域发表了791篇文章,是有记录的最高数量。我们的文献计量分析提供了跨多个维度的DENV研究的全面映射,包括媒介生态学,病毒学,和新兴疗法。该研究描绘了一个复杂的免疫反应基因网络,包括IFNA1、DDX58、IFNB1、STAT1、IRF3和NFKB1,突出了重要趋势和新兴主题,特别是气候变化和新爆发对疾病传播的影响。我们的研究结果详细介绍了关键候选疫苗的进展和现状,包括有执照的登瓦夏,更新的疫苗,如Qdenga和TV003,以及更新的临床试验。该研究强调了登革热抗病毒治疗和媒介控制策略的重大进展,强调AT-752和JNJ-1802等创新候选药物,以及用利巴韦林等药物重新利用的潜力,Remdesivir,还有洛匹那韦.此外,它讨论了生物防治方法,包括引入Wolbachia感染的蚊子和基因编辑技术。
结论:本文献计量研究强调了跨学科合作在推进DENV研究中的关键作用,确定关键趋势和需要进一步探索的领域,包括宿主病毒动力学,抗病毒药物和疫苗的开发和应用,以及人工智能的使用。它主张加强跨学科的伙伴关系,以有效应对DENV带来的挑战。
BACKGROUND: Dengue virus (DENV) is the most widespread arbovirus. The World Health Organization (WHO) declared dengue one of the top 10 global health threats in 2019. However, it has been underrepresented in bibliometric analyses. This study employs bibliometric analysis to identify research hotspots and trends, offering a comprehensive overview of the current research dynamics in this field.
RESULTS: We present a report spanning from 1995 to 2023 that provides a unique longitudinal analysis of Dengue virus (DENV) research, revealing significant trends and shifts not extensively covered in previous literature. A total of 10,767 DENV-related documents were considered, with a notable increase in publications, peaking at 747 articles in 2021. Plos Neglected Tropical Diseases has become the leading journal in Dengue virus research, publishing 791 articles in this field-the highest number recorded. Our bibliometric analysis provides a comprehensive mapping of DENV research across multiple dimensions, including vector ecology, virology, and emerging therapies. The study delineates a complex network of immune response genes, including IFNA1, DDX58, IFNB1, STAT1, IRF3, and NFKB1, highlighting significant trends and emerging themes, particularly the impacts of climate change and new outbreaks on disease transmission. Our findings detail the progress and current status of key vaccine candidates, including the licensed Dengvaxia, newer vaccines such as Qdenga and TV003, and updated clinical trials. The study underscores significant advancements in antiviral therapies and vector control strategies for dengue, highlighting innovative drug candidates such as AT-752 and JNJ-1802, and the potential of drug repurposing with agents like Ribavirin, Remdesivir, and Lopinavir. Additionally, it discusses biological control methods, including the introduction of Wolbachia-infected mosquitoes and gene-editing technologies.
CONCLUSIONS: This bibliometric study underscores the critical role of interdisciplinary collaboration in advancing DENV research, identifying key trends and areas needing further exploration, including host-virus dynamics, the development and application of antiviral drugs and vaccines, and the use of artificial intelligence. It advocates for strengthened partnerships across various disciplines to effectively tackle the challenges posed by DENV.